RhumbLine Advisers: Tenet Healthcare THC Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 51.9 M | Venta |
202,901
-12,921
| -6% | -USD 3.18 M | 0.04% | 354 |
|
|
2026
Q2 | USD 40.4 M | Venta |
215,822
-8,491
| -4% | -USD 1.56 M | 0.03% | 467 |
|
|
2026
Q1 | USD 42.3 M | Venta |
224,313
-161
| -0.1% | -USD 33.9 k | 0.04% | 409 |
|
|
2025
Q4 | USD 44.6 M | Venta |
224,474
-14,178
| -6% | -USD 2.87 M | 0.04% | 399 |
|
|
2025
Q3 | USD 48.5 M | Venta |
238,652
-12,556
| -5% | -USD 2.23 M | 0.04% | 375 |
|
|
2025
Q2 | USD 44.2 M | Venta |
251,208
-4,549
| -2% | -USD 685 k | 0.04% | 401 |
|
|
2025
Q1 | USD 34.4 M | Venta |
255,757
-4,338
| -2% | -USD 571 k | 0.03% | 457 |
|
|
2024
Q4 | USD 32.8 M | Venta |
260,095
-6,280
| -2% | -USD 934 k | 0.03% | 471 |
|
|
2024
Q3 | USD 44.3 M | Venta |
266,375
-8,454
| -3% | -USD 1.28 M | 0.04% | 376 |
|
|
2024
Q2 | USD 36.6 M | Venta |
274,829
-10,288
| -4% | -USD 1.24 M | 0.03% | 415 |
|
|
2024
Q1 | USD 30 M | Venta |
285,117
-11,823
| -4% | -USD 1.06 M | 0.03% | 506 |
|
|
2023
Q4 | USD 22.4 M | Venta |
296,940
-8,797
| -3% | -USD 558 k | 0.02% | 618 |
|
|
2023
Q3 | USD 20.1 M | Venta |
305,737
-6,354
| -2% | -USD 475 k | 0.02% | 630 |
|
|
2023
Q2 | USD 25.4 M | Venta |
312,091
-7,787
| -2% | -USD 554 k | 0.03% | 521 |
|
|
2023
Q1 | USD 19 M | Venta |
319,878
-6,577
| -2% | -USD 366 k | 0.02% | 632 |
|
|
2022
Q4 | USD 15.9 M | Compra |
326,455
+27,097
| +9% | +USD 1.25 M | 0.02% | 703 |
|
|
2022
Q3 | USD 15.4 M | Compra |
299,358
+8,418
| +3% | +USD 500 k | 0.02% | 664 |
|
|
2022
Q2 | USD 15.3 M | Venta |
290,940
-24,150
| -8% | -USD 1.68 M | 0.02% | 668 |
|
|
2022
Q1 | USD 27.1 M | Venta |
315,090
-2,455
| -0.8% | -USD 202 k | 0.03% | 445 |
|
|
2021
Q4 | USD 25.9 M | Venta |
317,545
-8,625
| -3% | -USD 630 k | 0.03% | 498 |
|
|
2021
Q3 | USD 21.7 M | Compra |
326,170
+157
| +0% | +USD 11.1 k | 0.03% | 542 |
|
|
2021
Q2 | USD 21.8 M | Venta |
326,013
-10,683
| -3% | -USD 663 k | 0.03% | 558 |
|
|
2021
Q1 | USD 17.5 M | Venta |
336,696
-8,676
| -3% | -USD 439 k | 0.02% | 659 |
|
|
2020
Q4 | USD 13.8 M | Compra |
345,372
+27,592
| +9% | +USD 890 k | 0.02% | 737 |
|
|
2020
Q3 | USD 7.79 M | Venta |
317,780
-42,411
| -12% | -USD 1.08 M | 0.01% | 896 |
|
|
2020
Q2 | USD 6.52 M | Compra |
360,191
+55,164
| +18% | +USD 1.09 M | 0.01% | 1040 |
|
|
2020
Q1 | USD 4.39 M | Compra |
305,027
+848
| +0.3% | +USD 24.3 k | 0.01% | 1098 |
|
|
2019
Q4 | USD 11.6 M | Venta |
304,179
-1,788
| -0.6% | -USD 53.6 k | 0.02% | 744 |
|
|
2019
Q3 | USD 6.77 M | Compra |
305,967
+29,046
| +10% | +USD 619 k | 0.01% | 1016 |
|
|
2019
Q2 | USD 5.72 M | Compra |
276,921
+30,241
| +12% | +USD 697 k | 0.01% | 1116 |
|
|
2019
Q1 | USD 7.11 M | Compra |
246,680
+502
| +0.2% | +USD 12.4 k | 0.01% | 962 |
|
|
2018
Q4 | USD 4.22 M | Compra |
246,178
+102,094
| +71% | +USD 2.47 M | 0.01% | 1207 |
|
|
2018
Q3 | USD 4.1 M | Venta |
144,084
-7,178
| -5% | -USD 237 k | 0.01% | 1236 |
|
|
2018
Q2 | USD 5.08 M | Compra |
151,262
+4,449
| +3% | +USD 138 k | 0.01% | 1084 |
|
|
2018
Q1 | USD 3.56 M | Venta |
146,813
-8,006
| -5% | -USD 159 k | 0.01% | 1264 |
|
|
2017
Q4 | USD 2.35 M | Compra |
154,819
+9,078
| +6% | +USD 128 k | ﹤0.01% | 1531 |
|
|
2017
Q3 | USD 2.4 M | Compra |
145,741
+5,163
| +4% | +USD 87.5 k | 0.01% | 1499 |
|
|
2017
Q2 | USD 2.72 M | Venta |
140,578
-12,055
| -8% | -USD 210 k | 0.01% | 1378 |
|
|
2017
Q1 | USD 2.7 M | Compra |
152,633
+3,998
| +3% | +USD 74.2 k | 0.01% | 1379 |
|
|
2016
Q4 | USD 2.21 M | Compra |
148,635
+6,887
| +5% | +USD 124 k | 0.01% | 1385 |
|
|
2016
Q3 | USD 3.21 M | Venta |
141,748
-9,555
| -6% | -USD 249 k | 0.01% | 1128 |
|
|
2016
Q2 | USD 4.18 M | Compra |
151,303
+18,635
| +14% | +USD 551 k | 0.01% | 912 |
|
|
2016
Q1 | USD 3.84 M | Compra |
132,668
+412
| +0.3% | +USD 10.7 k | 0.01% | 984 |
|
|
2015
Q4 | USD 4.01 M | Compra |
132,256
+5,265
| +4% | +USD 173 k | 0.01% | 935 |
|
|
2015
Q3 | USD 4.69 M | Venta |
126,991
-4,347
| -3% | -USD 225 k | 0.02% | 843 |
|
|
2015
Q2 | USD 7.6 M | Compra |
131,338
+6,162
| +5% | +USD 315 k | 0.02% | 646 |
|
|
2015
Q1 | USD 6.2 M | Compra |
125,176
+515
| +0.4% | +USD 24.1 k | 0.02% | 732 |
|
|
2014
Q4 | USD 6.32 M | Venta |
124,661
-1,085
| -0.9% | -USD 56.7 k | 0.02% | 673 |
|
|
2014
Q3 | USD 7.47 M | Venta |
125,746
-3,583
| -3% | -USD 200 k | 0.02% | 574 |
|
|
2014
Q2 | USD 6.07 M | Venta |
129,329
-8,989
| -6% | -USD 406 k | 0.02% | 706 |
|
|
2014
Q1 | USD 5.92 M | Venta |
138,318
-6,453
| -4% | -USD 285 k | 0.02% | 736 |
|
|
2013
Q4 | USD 6.1 M | Venta |
144,771
-20,564
| -12% | -USD 895 k | 0.02% | 718 |
|
|
2013
Q3 | USD 6.81 M | Compra |
165,335
+2,442
| +1% | +USD 102 k | 0.02% | 665 |
|
|
2013
Q2 | USD 7.51 M | Compra |
+162,893
| Nuevas | +USD 7.29 M | 0.02% | 585 |
|
Otros fondos que tienen THC en su portafolio
Posición de RhumbLine Advisers en THC: resumen de T3 2026
RhumbLine Advisers redujo su participación en Tenet Healthcare (THC) en 6% durante T3 2026, al vender acciones por un valor estimado de USD 3.18 M y quedarse con 202,901 acciones valuadas en USD 51.9 M. La posición representa 0.04% del portafolio y ocupa el puesto #354.
RhumbLine Advisers reportó por primera vez una posición en THC en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 784 fondos que sigue Wall St. Rank mantienen una posición en THC.
- Al cierre de T3 2026, RhumbLine Advisers tenía 202,901 acciones de Tenet Healthcare con un valor de USD 51.9 M.
- RhumbLine Advisers vendió 12,921 acciones de Tenet Healthcare en T3 2026, por un valor estimado de USD 3.18 M.
- Tenet Healthcare representó el 0.04% del portafolio de RhumbLine Advisers en T3 2026 y fue su posición número 354.
- RhumbLine Advisers reportó por primera vez una posición en Tenet Healthcare en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 784 fondos que sigue Wall St. Rank tenían Tenet Healthcare en su portafolio.
Según el informe 13F de RhumbLine Advisers correspondiente a T3 2026, presentado el 10 nov 2026.